ArticleScience translational medicine2018
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 247 papers.
0numbers the graph read from it
0cells of the map it votes in
247citing papers in PubMed
37.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
247 citing papers in PubMed, 373 citations in OpenAlex.
- Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.Journal for immunotherapy of cancer · 2025Trial
- Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives.Microorganisms · 2026Review
- Optimizing oncolytic reovirus therapy in hepatocellular carcinoma: A single dose enhances immune modulation and tumor delivery.Molecular therapy. Oncology · 2026Article
- Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML).British journal of cancer · 2026Article
- Review
- Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.International journal of cancer · 2026Article
- PD-L1 Immuno-PET Reveals Systemic Effects of Localized Oncolytic Virotherapy in a Mouse Model of Head and Neck Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal · 2026Review
- Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation.Viruses · 2026Review
- Spatial control of genome editing activity enables localized immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death.Molecular therapy. Oncology · 2026Article
- Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.International journal of molecular sciences · 2026Review
- Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Review
- Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells.ImmunoTargets and therapy · 2026Article
- Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy.Nature cancer · 2026Article
- Intracranial injection of genetically modified, mosquito non-transmissible Zika virus: Safety in primates and ramifications for brain tumor therapy.Cell reports. Medicine · 2025Article
- Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy.Advanced pharmaceutical bulletin · 2025Review
- Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.Lancet (London, England) · 2025Review
187 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
39 authors at 8 institutions in 3 countries.
Adel SamsonLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK. a.samson@leeds.ac.uk alan.melcher@icr.ac.uk s.c.short@leeds.ac.uk.ORCID 0000-0002-3081-7850
Karen J ScottLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
David TaggartLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0001-8781-4936
Emma J WestLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Erica WilsonLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-0441-728X
Gerard J NuovoOhio State University, Comprehensive Cancer Centre, Columbus, OH 43210, USA.ORCID 0000-0002-5351-4721
Simon ThomsonLeeds Teaching Hospitals National Health Service Trust, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0003-4827-1961
Robert CornsLeeds Teaching Hospitals National Health Service Trust, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Ryan K MathewLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-2609-9876
Martin J FullerLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Timothy J KottkeDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Jill M ThompsonDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Elizabeth J IlettLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-9875-0322
Julia V CockleLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0001-9437-4633
Philip van HilleLeeds Teaching Hospitals National Health Service Trust, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Gnanamurthy SivakumarLeeds Teaching Hospitals National Health Service Trust, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Euan S PolsonLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Samantha J TurnbullLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-1664-3292
Elizabeth S AppletonLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Gemma MignecoLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Ailsa S RoseLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-1382-969X
Matthew C CoffeyOncolytics Biotech, Calgary, Alberta T2N 1X7, Canada.
Deborah A BeirneLeeds Teaching Hospitals National Health Service Trust, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-6791-278X
Fiona J CollinsonLeeds Institute of Clinical Trials Research, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK.
Christy RalphLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0001-5581-2987
D Alan AnthoneyLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0001-5695-8312
Christopher J TwelvesLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Andrew J FurnessUniversity College London, London WC1 6BT, UK.
Sergio A QuezadaUniversity College London, London WC1 6BT, UK.ORCID 0000-0002-9763-1700
Heiko WurdakLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0003-4385-4324
Fiona Errington-MaisLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0003-2155-534X
Hardev PandhaUniversity of Surrey, Guildford GU2 7XH, UK.
Kevin J HarringtonInstitute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.
Peter J SelbyLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-3782-069X
Richard G VileDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Stephen D GriffinLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-7233-5243
Lucy F SteadLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.ORCID 0000-0002-9550-4150
Susan C ShortLeeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, St James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK. a.samson@leeds.ac.uk alan.melcher@icr.ac.uk s.c.short@leeds.ac.uk.ORCID 0000-0003-4423-7256
Alan A MelcherInstitute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK. a.samson@leeds.ac.uk alan.melcher@icr.ac.uk s.c.short@leeds.ac.uk.ORCID 0000-0002-2042-3380
University of Leeds · GBLeeds Teaching Hospitals NHS Trust · GBMayo Clinic · USInstitute of Cancer Research · GBUniversity College London · GBOncolytics Biotech (Canada) · CAThe Ohio State University · USUniversity of Surrey · GB
Funding
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic VirusR01CA175386 · NCI · MAYO CLINIC ROCHESTER · PI VILE, RICHARD G. · 2014 to 2018
$1.3MCancer Research UK 10065Cancer Research UK 12100Cancer Research UK 20764Cancer Research UK 21855Cancer Research UK 22246Cancer Research UK 22951Cancer Research UK A7086Department of Health RP-PG-0707-10101NCI NIH HHS R01 CA175386
Abstract
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined by tumor programmed death ligand 1 (PD-L1) expression. We hypothesized that preconditioning of the tumor immune microenvironment using targeted, virus-mediated interferon (IFN) stimulation would up-regulate tumor PD-L1 protein expression and increase cytotoxic T cell infiltration, improving the efficacy of subsequent checkpoint blockade. Oncolytic viruses (OVs) represent a promising form of cancer immunotherapy. For brain tumors, almost all studies to date have used direct intralesional injection of OV, because of the largely untested belief that intravenous administration will not deliver virus to this site. We show, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human
Indexed as
AnimalsBrain NeoplasmsGliomaHumansImmunotherapyMiceMice, Inbred C57BLOncolytic VirusesProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.